MDACC Study No:RTOG0929 ( NCT No: NCT01026493)
Title:A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
Principal Investigator:John DeGroot
Treatment Agent:ABT-888; Temozolomide
Study Status:Closed
Study Description:The goal of Phase I of this clinical research study is to find the highest
tolerable dose of the combination of ABT-888 and temozolomide that can be given
to patients with glioblastoma.

The goal of Phase II of this clinical research study is to learn if the
combination of temozolomide and ABT-888 can help to control glioblastoma. Two
(2) different dose schedules of the study drug combination will also be

The safety of these drug combinations will also be studied in both phases.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:ABT-888
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Radiation Therapy Oncology Group (RTOG)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults